ReviewCancers2022
The Role of Genomics and Proteomics in Lung Cancer Early Detection and Treatment.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Circulating proteins associated with histological subtypes of lung cancer from genetic and population-based perspectives.PLoS genetics · 2025Pooled it
- Diagnostic Accuracy of Exosomal Long Noncoding RNAs in Diagnosis of NSCLC: A Meta-Analysis.Molecular diagnosis & therapy · 2024Pooled it
- Liquid biopsy in non-small cell lung cancer: a meta-analysis of state-of-the-art and future perspectives.Frontiers in genetics · 2023Pooled it
- Relationship between expression of derived factor-1CXC chemokine receptor 4 in tumor tissues of patients with non-small cell lung cancer and postoperative lymph node metastasis.Journal of molecular histology · 2026Article
- Development and validation of hypermethylated gene markers in cervical cytological samples for detecting endometrial cancer (EndoMethy-I trial).Frontiers in oncology · 2026Article
- Brahmi (Bacopa monnieri) plant preparation facilitates to enhance the activities of dendritic cells to control non-small cell lung cancer (NSCLC).Journal of cancer research and clinical oncology · 2025Article
- Unveiling unique protein and phosphorylation signatures in lung adenocarcinomas with and without ALK, EGFR, and KRAS genetic alterations.Molecular oncology · 2025Article
- Advancing Non-Small-Cell Lung Cancer Management Through Multi-Omics Integration: Insights from Genomics, Metabolomics, and Radiomics.Diagnostics (Basel, Switzerland) · 2025Review
- Novel therapeutic strategies for non-small cell lung cancer: Combination therapies with immune checkpoint inhibitors (Review).Oncology letters · 2025Review
- Non-coding RNAs and regulation of the PI3K signaling pathway in lung cancer: Recent insights and potential clinical applications.Non-coding RNA research · 2025Review
- Investigating causal relationships between plasma proteins and lung adenocarcinoma: result from proteomics and Mendelian randomization study.Discover oncology · 2025Article
- Applications and challenges of multi-omics approaches in lung cancer research and precision treatment.Frontiers in genetics · 2025Review
- The Role of Immunotherapy in Lung Cancer Treatment: Current Strategies, Future Directions, and Insights into Metastasis and Immune Microenvironment.Current gene therapy · 2025Review
- Advances in early detection of non-small cell lung cancer: A comprehensive review.Cancer medicine · 2024Review
- Lung Cancer Subtyping: A Short Review.Cancers · 2024Review
- Recent Advancements in Minimally Invasive Surgery for Early Stage Non-Small Cell Lung Cancer: A Narrative Review.Journal of clinical medicine · 2024Review
- Cross-omics strategies and personalised options for lung cancer immunotherapy.Frontiers in immunology · 2024Review
- Exploring Splicing Modulation as an Innovative Approach to Combat Pancreatic Cancer: SF3B1 Emerges as a Prognostic Indicator and Therapeutic Target.International journal of biological sciences · 2024Article
- ERS International Congress 2022: highlights from the Thoracic Oncology Assembly.ERJ open research · 2023Article
- Identification of m7G-Related miRNA Signatures Associated with Prognosis, Oxidative Stress, and Immune Landscape in Lung Adenocarcinoma.Biomedicines · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the leading cause of cancer-related death worldwide, with non-small-cell lung cancer (NSCLC) being the primary type. Unfortunately, it is often diagnosed at advanced stages, when therapy leaves patients with a dismal prognosis. Despite the advances in genomics and proteomics in the past decade, leading to progress in developing tools for early diagnosis, targeted therapies have shown promising results; however, the 5-year survival of NSCLC patients is only about 15%. Low-dose computed tomography or chest X-ray are the main types of screening tools. Lung cancer patients without specific, actionable mutations are currently treated with conventional therapies, such as platinum-based chemotherapy; however, resistances and relapses often occur in these patients. More noninvasive, inexpensive, and safer diagnostic methods based on novel biomarkers for NSCLC are of paramount importance. In the current review, we summarize genomic and proteomic biomarkers utilized for the early detection and treatment of NSCLC. We further discuss future opportunities to improve biomarkers for early detection and the effective treatment of NSCLC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.